Latham Advises Nichi-Iko Pharmaceutical on Sale of Sagent Pharmaceuticals and Omega Laboratories to Ellimist Singapore

Latham & Watkins has advised Nichi-Iko Pharmaceutical Co., Ltd. (Nichi-Iko Pharmaceutical), a Tokyo Stock Exchange-listed Japanese company that focuses on manufacturing and selling pharmaceutical and medical products, on the sale of its US-business, i.e., of all issued and outstanding shares of its wholly owned subsidiaries, Sagent Pharmaceuticals, based in Wyoming, and Omega Laboratories Ltd., based in Montreal, to Singapore company Ellimist Singapore Pte. Ltd.

The Latham team was led by Hamburg partner Henning C. Schneider and Chicago partners Jason Morelli and Sean Parish, with associate Dalton Morgan Powell. Advice was also provided on tax matters by Chicago partner Rene de Vera and on finance matters by Chicago partner James Ktsanes and New York partner George Klidonas.